Delisting risk
YARW · NASDAQ · Biotechnology

Yarrow Bioscience (YARW)

Develops a TSHR-blocking antibody for Graves’ disease and thyroid eye disease.

$29.83
At close−1.15 (−3.71%)

No news on record for this listing yet.